Sarina Tanimoto Sells 2,343 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 2,343 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $9.02, for a total transaction of $21,133.86. Following the completion of the sale, the insider now directly owns 1,745,082 shares of the company’s stock, valued at approximately $15,740,639.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Sarina Tanimoto also recently made the following trade(s):

• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.00, for a total transaction of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total transaction of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total transaction of $6,307.00.

ARS Pharmaceuticals Stock Down 0.4 %

NASDAQ:SPRY opened at $9.96 on Thursday. The business’s 50-day moving average price is $7.75 and its 200 day moving average price is $5.80. The firm has a market cap of $961.14 million, a P/E ratio of -17.47 and a beta of 0.78. ARS Pharmaceuticals, Inc. has a 52-week low of $2.55 and a 52-week high of $10.20.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SPRY. Leerink Partnrs raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th. SVB Leerink upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $6.00 to $18.00 in a research note on Tuesday, March 5th. William Blair upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $19.00 target price on shares of ARS Pharmaceuticals in a research note on Monday, March 11th.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its position in ARS Pharmaceuticals by 12.7% during the 3rd quarter. Legal & General Group Plc now owns 28,157 shares of the company’s stock worth $106,000 after acquiring an additional 3,178 shares during the period. Creative Planning boosted its position in ARS Pharmaceuticals by 11.7% during the 4th quarter. Creative Planning now owns 31,201 shares of the company’s stock worth $171,000 after acquiring an additional 3,270 shares during the period. Charles Schwab Investment Management Inc. boosted its position in ARS Pharmaceuticals by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,550 shares of the company’s stock worth $1,806,000 after acquiring an additional 5,147 shares during the period. American Century Companies Inc. boosted its position in ARS Pharmaceuticals by 11.1% during the 3rd quarter. American Century Companies Inc. now owns 51,521 shares of the company’s stock worth $195,000 after acquiring an additional 5,153 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after buying an additional 5,575 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.